This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sophiris Bio Announces 12 Month Follow-Up Data From Phase 2b TRIUMPH Clinical Trial Of PRX302 In Patients With Benign Prostatic Hyperplasia

Single administration of PRX302 as a short outpatient procedure provided sustained benefit over 12 months

SAN DIEGO, CA and VANCOUVER, Oct. 9, 2012 /PRNewswire/ - Sophiris Bio Inc. (TSX: SHS) today released top line data from the 12 month follow up of patients receiving PRX302 for the treatment of benign prostatic hyperplasia (BPH, or enlarged prostate) in a Phase 2b study (TRIUMPH). PRX302 produced a clinically significant improvement in the subjective symptom score (International Prostate Symptom Score, or IPSS) and the objective measure of mean peak urinary flow rate (Qmax) sustained over 12 months. As previously reported, the trial met the primary clinical endpoint of the study, which was to demonstrate the efficacy of PRX302 at 90 days post-treatment by a statistically significant improvement from baseline in IPSS when compared to placebo (vehicle only injection). Consistent with the results previously reported for this study, PRX302 continued to be well tolerated with no erectile function side effects during the 12 months following treatment.

PRX302 treatment resulted in approximately 8 to 9-point average reduction of IPSS that was sustained over 12 months. The IPSS is a patient self-administered questionnaire of lower urinary tract symptoms with a possible range of 0 to 35 points, with 0 being no symptoms and 35 being the high end of severe symptoms. This average improvement in IPSS was a clinically meaningful 2.8 to 4.1 point reduction over and above the IPSS improvement observed in the placebo group. In addition, PRX302 treatment resulted in a ~3 mL/sec average increase in Qmax, which was sustained over 12 months. Both IPSS and Qmax are validated clinical endpoints used for BPH product regulatory approvals.

PRX302 was well tolerated in this study with patients who had moderate to severe lower urinary tract symptoms due to BPH, about half of whom had previously taken oral medication for BPH. The side effect profile was favorable with most of the side effects attributed to the injection procedure itself and not related to drug toxicity.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs